<?xml version="1.0"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><atom:link href="http://www.cnbc.com/id/10000108/device/rss/rss.html" rel="self" type="application/rss+xml" /><title>Health Care</title><description><![CDATA[Healthcare]]></description><link>http://www.cnbc.com/id/10000108</link><pubDate>Wed, 13 Feb 2013 17:22 GMT</pubDate><lastBuildDate>Wed, 13 Feb 2013 17:22 GMT</lastBuildDate><language>en-us</language><ttl>60</ttl><item><title>UPDATE 4-U.S. judge strikes age rules for 'morning-after' pill</title><description><![CDATA[NEW YORK, April 5- A federal judge on Friday ordered the U.S. Food and Drug Administration to make &quot;morning-after&quot; emergency contraception pills available without a prescription to all girls of reproductive age and criticized the Obama administration for interfering with the process for political purposes.]]></description><link>http://www.cnbc.com/id/100620195</link><pubDate>Fri, 05 Apr 2013 19:00 GMT</pubDate><guid isPermaLink="false">guid_100620195</guid> </item>  <item><title>InVivo Therapeutics gets approval for human trials</title><description><![CDATA[CAMBRIDGE, Mass.-- InVivo Therapeutics Holdings Corp. said Friday that the Food and Drug Administration will allow it to start human trials of an experimental product that is intended to treat spinal cord injuries. The Cambridge, Mass., company said there are no FDA- approved treatments that intervene directly in the spinal cord following an injury.]]></description><link>http://www.cnbc.com/id/100620113</link><pubDate>Fri, 05 Apr 2013 18:35 GMT</pubDate><guid isPermaLink="false">guid_100620113</guid> </item>  <item><title>Rigel slumps on rheumatoid arthritis drug results</title><description><![CDATA[NEW YORK-- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped develop.]]></description><link>http://www.cnbc.com/id/100619533</link><pubDate>Fri, 05 Apr 2013 15:15 GMT</pubDate><guid isPermaLink="false">guid_100619533</guid> </item>  <item><title>Kan. abortion clinic opens in slain doc's building</title><description><![CDATA[WICHITA, Kan.-- A new clinic offering abortions and other women&#039;s medical services saw its first patient Thursday in the Wichita building where a slain Kansas abortion provider had practiced.  &quot;We have been working a long time, really hard to get this open to provide services to women in Wichita,&quot; said Kerry Townsend Jacob, the group&#039;s spokeswoman.]]></description><link>http://www.cnbc.com/id/100619047</link><pubDate>Fri, 05 Apr 2013 12:48 GMT</pubDate><guid isPermaLink="false">guid_100619047</guid> </item>  <item><title>After long fight, Roche to release all Tamiflu drug data</title><description><![CDATA[LONDON, April 4- After a lengthy fight, Swiss drugmaker Roche Holding AG said it had agreed to hand over data from all clinical trials of its best-selling flu drug Tamiflu to a group of outside researchers. Sales of the drug hit close to $3 billion in 2009 due to the H1N1 swine flu pandemic, although they have since declined.]]></description><link>http://www.cnbc.com/id/100617656</link><pubDate>Thu, 04 Apr 2013 20:40 GMT</pubDate><guid isPermaLink="false">guid_100617656</guid> </item>  <item><title>'Slow Crawl' to Prosperity as Jobs Growth 'Dives'</title><description><![CDATA[Mirroring the broader economy, small-business owners&#039; plans to hire are taking a &quot;dive&quot; as owners remain pessimistic and see little reason for new jobs. ]]></description><link>http://www.cnbc.com/id/100613971</link><pubDate>Thu, 04 Apr 2013 16:43 GMT</pubDate><guid isPermaLink="false">guid_100613971</guid> </item>  <item><title>Navidea advances on new Lymphoseek study data</title><description><![CDATA[NEW YORK-- Shares of Navidea Biopharmaceuticals Inc. rose Thursday after the company reported favorable new clinical trial results for its imaging agent Lymphoseek. The Food and Drug Administration approved Lymphoseek March 13 to help doctors locate lymph nodes in patients with breast cancer and skin cancer.]]></description><link>http://www.cnbc.com/id/100616350</link><pubDate>Thu, 04 Apr 2013 14:04 GMT</pubDate><guid isPermaLink="false">guid_100616350</guid> </item>  <item><title>Valeant says generic approval could lower profit</title><description><![CDATA[Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year.]]></description><link>http://www.cnbc.com/id/100616297</link><pubDate>Thu, 04 Apr 2013 13:58 GMT</pubDate><guid isPermaLink="false">guid_100616297</guid> </item>  <item><title>New Bird Flu Cases Rise in China, Three Deaths</title><description><![CDATA[China has found two cases of a new strain of the deadly epidemic, sparking fears of a global resurgence.]]></description><link>http://www.cnbc.com/id/100614703</link><pubDate>Thu, 04 Apr 2013 00:21 GMT</pubDate><guid isPermaLink="false">guid_100614703</guid> </item>  <item><title>Businesses to IRS: Change Forgotten Obamacare Tax </title><description><![CDATA[Businesses and wealthy owners of estates ask the IRS for changes to a 3.8 percent tax on investment income to fund Obamacare.]]></description><link>http://www.cnbc.com/id/100613062</link><pubDate>Wed, 03 Apr 2013 15:12 GMT</pubDate><guid isPermaLink="false">guid_100613062</guid> </item>  <item><title>Valeant Pharma boosts offer for Obagi to $418M</title><description><![CDATA[LONG BEACH, Calif.-- Obagi Medical Products Inc. said Wednesday that Canadian drugmaker Valeant Pharmaceuticals boosted its offer to buy the dermatology products maker, topping a bid made a day ago by a German rival.]]></description><link>http://www.cnbc.com/id/100613077</link><pubDate>Wed, 03 Apr 2013 14:25 GMT</pubDate><guid isPermaLink="false">guid_100613077</guid> </item>  <item><title>UPDATE 2-Royalty Pharma gets May deadline to firm up Elan offer</title><description><![CDATA[*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland&#039;s Takeover Panel said on Wednesday.]]></description><link>http://www.cnbc.com/id/100612900</link><pubDate>Wed, 03 Apr 2013 13:35 GMT</pubDate><guid isPermaLink="false">guid_100612900</guid> </item>  <item><title>UPDATE 1-Royalty Pharma given May deadline to firm up Elan offer</title><description><![CDATA[*Elan welcomes Irish Takeover Panel deadline for bid. DUBLIN, April 3- U.S. investment firm Royalty Pharma, which is considering a $6.6- billion bid for Irish drugmaker Elan, must make a firm offer by May 10 or walk away, Ireland&#039;s Takeover Panel said on Wednesday.]]></description><link>http://www.cnbc.com/id/100612456</link><pubDate>Wed, 03 Apr 2013 12:10 GMT</pubDate><guid isPermaLink="false">guid_100612456</guid> </item>  <item><title>UPDATE 1-AstraZeneca buys early-stage U.S. biotech firm</title><description><![CDATA[LONDON, April 3- AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a new type of cholesterol medicine.]]></description><link>http://www.cnbc.com/id/100611971</link><pubDate>Wed, 03 Apr 2013 07:53 GMT</pubDate><guid isPermaLink="false">guid_100611971</guid> </item>  <item><title>Talking Numbers: Buy Humana or United Healthcare?</title><description><![CDATA[Which health insurance stock can keep your portfolio strong? Enis Taner, RiskReversal.com and Zachary Karabell, River Twice Research, discuss. ]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158347</link><pubDate>Tue, 02 Apr 2013 19:30 GMT</pubDate><guid isPermaLink="false">guid_100610558</guid> </item>  <item><title>UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers</title><description><![CDATA[*Optimer could get $15- $16/ shr- analyst. April 2- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker. The report also named AstraZeneca PLC and Japan&#039;s Astellas Pharma Inc as potential buyers.]]></description><link>http://www.cnbc.com/id/100610365</link><pubDate>Tue, 02 Apr 2013 18:29 GMT</pubDate><guid isPermaLink="false">guid_100610365</guid> </item>  <item><title>Vanguard Health rebounds on Medicaid contract</title><description><![CDATA[NASHVILLE, Tenn.-- Shares of hospital operator Vanguard Health Systems took back some ground Wednesday after the company said it had secured a three-year contract to manage Medicaid patients in Arizona. It had said last month that Arizona wasn&#039;t renewing a bigger Medicaid contract.]]></description><link>http://www.cnbc.com/id/100610363</link><pubDate>Tue, 02 Apr 2013 18:28 GMT</pubDate><guid isPermaLink="false">guid_100610363</guid> </item>  <item><title>HMOs Pop on Medicare Decision</title><description><![CDATA[HMO stocks jumped on decisions on 2013 Medicare rates, but is this all roses? CNBC&#039;s Scott Cohn and Ipsita Smolinski, offer insight. ]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158535</link><pubDate>Tue, 02 Apr 2013 18:10 GMT</pubDate><guid isPermaLink="false">guid_100610370</guid> </item>  <item><title>New-look Sarepta eyes approval for muscular dystrophy drug</title><description><![CDATA[*Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug. *Analysts expect company to relay FDA feedback in April. April 2- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.]]></description><link>http://www.cnbc.com/id/100610269</link><pubDate>Tue, 02 Apr 2013 17:51 GMT</pubDate><guid isPermaLink="false">guid_100610269</guid> </item>  <item><title>HMOs: A Reversal of Fortune</title><description><![CDATA[HMO stocks jumped on decisions on 2013 Medicare rates, with CNBC&#039;s Scott Cohn. ]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158528</link><pubDate>Tue, 02 Apr 2013 17:42 GMT</pubDate><guid isPermaLink="false">guid_100610324</guid> </item>  <item><title>HMOs Jump on 2013 Medicare Rates</title><description><![CDATA[Health insurance stocks like Humana broke out sharply on Monday after the CMS increased the Medicare Advantage rate. The FMHR traders and Steve Grasso discuss how to play these stocks. Also, whether to get cautious on news the Dow has set a new intraday high in 12 of the past 20 trading sessions, with Jason Pride, Glenmede.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158374</link><pubDate>Tue, 02 Apr 2013 16:41 GMT</pubDate><guid isPermaLink="false">guid_100610101</guid> </item>  <item><title>HMO Stocks on a Surge</title><description><![CDATA[CNBC&#039;s Bertha Coombs explains how a change in budget calculations sent some health insurance shares higher.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158481</link><pubDate>Tue, 02 Apr 2013 15:32 GMT</pubDate><guid isPermaLink="false">guid_100609867</guid> </item>  <item><title>ANALYSIS-Big Pharma down, not out, after Indian patent blow</title><description><![CDATA[LONDON/ MUMBAI, April 2- Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world&#039;s eighth largest market for medicines by 2016..]]></description><link>http://www.cnbc.com/id/100609638</link><pubDate>Tue, 02 Apr 2013 14:48 GMT</pubDate><guid isPermaLink="false">guid_100609638</guid> </item>  <item><title>Health Insurers Soar on Medicare Rate Rise</title><description><![CDATA[CNBC&#039;s Bertha Coombs explains why the government&#039;s new program for Medicare and Medicaid has sent some insurers soaring.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158472</link><pubDate>Tue, 02 Apr 2013 14:32 GMT</pubDate><guid isPermaLink="false">guid_100609727</guid> </item>  <item><title>6th Annual World Autism Awareness Day</title><description><![CDATA[Bob and Suzanne Wright, co-founders of Autism Speaks, discuss the organization&#039;s efforts to foster research and raise awareness about Autism.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158427</link><pubDate>Tue, 02 Apr 2013 13:40 GMT</pubDate><guid isPermaLink="false">guid_100609341</guid> </item>  <item><title>Booster Shot For Health Insurers</title><description><![CDATA[Sarah James, Wedbush Securities analyst, reveals her outlook on health care companies, after a recent report indicates an estimated growth rate of 3.3% for insurers. ]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158275</link><pubDate>Tue, 02 Apr 2013 11:42 GMT</pubDate><guid isPermaLink="false">guid_100608806</guid> </item>  <item><title>UPDATE 2-Obagi Medical gets higher offer from Merz Pharma</title><description><![CDATA[April 2- Neurological and dermatology drugs maker Merz Pharma Group offered to buy cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada&#039;s Valeant Pharmaceuticals International Inc. Merz&#039;s $22- per-share bid represents a premium of 11 percent to Valeant&#039;s offer of $19.75.]]></description><link>http://www.cnbc.com/id/100610067</link><pubDate>Tue, 02 Apr 2013 04:44 GMT</pubDate><guid isPermaLink="false">guid_100610067</guid> </item>  <item><title>CMS Assumes No Change for 2014</title><description><![CDATA[Health insurance stocks are moving higher on the decision from the Center for Medicare Services--CMS says they will not propose a cut to Medicare reimbursement rates, reports CNBC&#039;s Bertha Coombs.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158265</link><pubDate>Mon, 01 Apr 2013 20:55 GMT</pubDate><guid isPermaLink="false">guid_100607374</guid> </item>  <item><title>Johnson &amp; Johnson Hits All-Time High</title><description><![CDATA[Johnson &amp; Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight. ]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158225</link><pubDate>Mon, 01 Apr 2013 18:38 GMT</pubDate><guid isPermaLink="false">guid_100606974</guid> </item>  <item><title>Health Care &amp; Your Retirement</title><description><![CDATA[Enrollment season for Medicare Advantage plans and Obama&#039;s health reform plan is six months away. One big question is how many people will show up to be insured, reports CNBC&#039;s Bertha Coombs.]]></description><link>http://video.cnbc.com/gallery/?play=1&amp;video=3000158211</link><pubDate>Mon, 01 Apr 2013 17:45 GMT</pubDate><guid isPermaLink="false">guid_100606864</guid> </item> </channel>   </rss